JP2011520965A5 - - Google Patents

Download PDF

Info

Publication number
JP2011520965A5
JP2011520965A5 JP2011510594A JP2011510594A JP2011520965A5 JP 2011520965 A5 JP2011520965 A5 JP 2011520965A5 JP 2011510594 A JP2011510594 A JP 2011510594A JP 2011510594 A JP2011510594 A JP 2011510594A JP 2011520965 A5 JP2011520965 A5 JP 2011520965A5
Authority
JP
Japan
Prior art keywords
inhibitor
sglt2
sglt2 inhibitor
uric acid
hyperuricemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011510594A
Other languages
English (en)
Japanese (ja)
Other versions
JP5820269B2 (ja
JP2011520965A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/044156 external-priority patent/WO2009143020A1/en
Publication of JP2011520965A publication Critical patent/JP2011520965A/ja
Publication of JP2011520965A5 publication Critical patent/JP2011520965A5/ja
Application granted granted Critical
Publication of JP5820269B2 publication Critical patent/JP5820269B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011510594A 2008-05-22 2009-05-15 Ｓｇｌｔ２阻害剤を使用する高尿酸血症の治療方法およびｓｇｌｔ２阻害剤を含有する組成物 Expired - Fee Related JP5820269B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5535208P 2008-05-22 2008-05-22
US61/055,352 2008-05-22
PCT/US2009/044156 WO2009143020A1 (en) 2008-05-22 2009-05-15 Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014128550A Division JP2014205700A (ja) 2008-05-22 2014-06-23 Ｓｇｌｔ２阻害剤を使用する高尿酸血症の治療方法およびｓｇｌｔ２阻害剤を含有する組成物

Publications (3)

Publication Number Publication Date
JP2011520965A JP2011520965A (ja) 2011-07-21
JP2011520965A5 true JP2011520965A5 (https=) 2012-06-14
JP5820269B2 JP5820269B2 (ja) 2015-11-24

Family

ID=40810833

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011510594A Expired - Fee Related JP5820269B2 (ja) 2008-05-22 2009-05-15 Ｓｇｌｔ２阻害剤を使用する高尿酸血症の治療方法およびｓｇｌｔ２阻害剤を含有する組成物
JP2014128550A Pending JP2014205700A (ja) 2008-05-22 2014-06-23 Ｓｇｌｔ２阻害剤を使用する高尿酸血症の治療方法およびｓｇｌｔ２阻害剤を含有する組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014128550A Pending JP2014205700A (ja) 2008-05-22 2014-06-23 Ｓｇｌｔ２阻害剤を使用する高尿酸血症の治療方法およびｓｇｌｔ２阻害剤を含有する組成物

Country Status (9)

Country Link
US (1) US8791077B2 (https=)
EP (2) EP2291189B1 (https=)
JP (2) JP5820269B2 (https=)
CN (1) CN102105153B (https=)
BR (1) BRPI0913129A2 (https=)
CA (1) CA2725047A1 (https=)
ES (1) ES2526930T3 (https=)
MX (1) MX2010012656A (https=)
WO (1) WO2009143020A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
PE20170306A1 (es) * 2010-06-16 2017-05-06 Takeda Pharmaceuticals Usa Inc Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
US20140093563A1 (en) * 2011-06-13 2014-04-03 Ranbaxy Laboratories Limited Febuxostat compositions
RU2014134845A (ru) * 2012-01-27 2016-03-20 Тейдзин Фарма Лимитед Терапевтическое средство против диабета
JP2016512817A (ja) * 2013-03-15 2016-05-09 ヤンセン ファーマシューティカ エヌ．ベー． 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ
PT2981269T (pt) 2013-04-04 2023-10-10 Boehringer Ingelheim Vetmedica Gmbh Tratamento de distúrbios metabólicos em animais equinos
ES2969764T3 (es) 2013-12-17 2024-05-22 Boehringer Ingelheim Vetmedica Gmbh Un inhibidor de SGLT-2 para usar en el tratamiento de un trastorno metabólico en animales felinos
CN115671290A (zh) 2014-01-23 2023-02-03 勃林格殷格翰动物保健有限公司 犬科动物中代谢紊乱的治疗
WO2015150299A2 (en) 2014-04-01 2015-10-08 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals
WO2016046150A1 (en) 2014-09-25 2016-03-31 Boehringer Ingelheim Vetmedica Gmbh Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
KR102659761B1 (ko) * 2015-08-27 2024-04-24 베링거잉겔하임베트메디카게엠베하 Sglt-2 억제제를 포함하는 액상 약제학적 조성물
KR101863604B1 (ko) * 2016-04-08 2018-06-04 한국 한의학 연구원 익지 추출물을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물
WO2018167589A1 (en) 2017-03-16 2018-09-20 Inventia Healthcare Private Limited Pharmaceutical composition comprising dapagliflozin
WO2019087239A1 (ja) * 2017-10-30 2019-05-09 合同会社カルナヘルスサポート 腎症治療剤
WO2019092770A1 (ja) * 2017-11-07 2019-05-16 合同会社カルナヘルスサポート 網膜疾患治療剤
US20210338648A1 (en) * 2018-10-01 2021-11-04 Astrazeneca Ab Methods and compositions for reducing serum uric acid
CA3121624A1 (en) * 2018-12-06 2020-06-11 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
US12145917B2 (en) 2018-12-06 2024-11-19 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
EP3934628A4 (en) * 2019-03-03 2022-12-14 Algatechnologies Ltd. COMPOSITIONS CONTAINING ALGAE POWDER AND THEIR USES
JP6831961B2 (ja) * 2019-10-23 2021-02-24 株式会社カルナヘルスサポート 網膜疾患治療剤
EP4064854A1 (en) 2019-11-28 2022-10-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors in the drying-off of non-human mammals
WO2021252630A1 (en) * 2020-06-10 2021-12-16 Arthrosi Therapeutics, Inc. Methods for treating or preventing chronic kidney disease

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346094A (en) * 1980-09-22 1982-08-24 Eli Lilly And Company 3-Aryl-5-isothiazolecarboxylic acids and related compounds used to lower uric acid levels
CA2102591C (en) 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
US5830873A (en) 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
JP2814950B2 (ja) 1994-05-11 1998-10-27 田辺製薬株式会社 血糖降下剤
JP3065235B2 (ja) 1995-11-07 2000-07-17 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JP3034192B2 (ja) 1995-11-07 2000-04-17 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JP3059088B2 (ja) 1995-11-07 2000-07-04 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JP3006513B2 (ja) 1995-11-07 2000-02-07 田辺製薬株式会社 医薬組成物
PT850948E (pt) 1996-12-26 2002-08-30 Tanabe Seiyaku Co Derivados propiofenona e processo para a preparacao dos mesmos
JPH10245391A (ja) 1997-03-03 1998-09-14 Dainippon Ink & Chem Inc ７−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
ES2337127T3 (es) 2000-11-02 2010-04-21 Ajinomoto Co., Inc. Nuevos derivados de pirazol y remedios contra la diabetes que los contienen.
US7087579B2 (en) 2001-02-26 2006-08-08 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and medicinal use thereof
JP4147111B2 (ja) * 2001-02-27 2008-09-10 キッセイ薬品工業株式会社 グルコピラノシルオキシピラゾール誘導体およびその医薬用途
WO2002080935A1 (en) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
AU2002254567B2 (en) 2001-04-11 2007-10-11 Bristol-Myers Squibb Company Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
CA2672001A1 (en) 2001-04-27 2002-11-07 Ajinomoto Co., Inc. N-substituted pyrazole-o-glycoside derivatives and therapeutic agent for diabetes containing the same
ATE369787T1 (de) 2001-06-20 2007-09-15 Purdue Research Foundation Druckmanschette mit körperbeleuchtung zur verwendung bei der optischen nichtinvasiven messung von blutparametern
MXPA04009229A (es) 2002-03-22 2004-11-26 Kissei Pharmaceutical Cristales derivados de glucopiranosiloxibencil benceno.
ES2363941T3 (es) 2003-03-14 2011-08-19 Astellas Pharma Inc. Derivados de c-glucósido para el tratamiento de diabetes.
EP1609799A4 (en) * 2003-04-01 2008-10-29 Taisho Pharmaceutical Co Ltd HETEROARYL-5-THIO-BETA-D-GLUCOPYRANOSIDE DERIVATIVES AND AGENTS AGAINST DIABETES THEREOF
US7439232B2 (en) 2003-04-01 2008-10-21 Taisho Pharmaceutical Co., Ltd. Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
JP2004359630A (ja) 2003-06-06 2004-12-24 Yamanouchi Pharmaceut Co Ltd ジフルオロジフェニルメタン誘導体及びその塩
US20050027128A1 (en) * 2003-07-30 2005-02-03 Robbins Timothy A. Substituted thiazoles
ES2531660T3 (es) 2003-08-01 2015-03-18 Mitsubishi Tanabe Pharma Corporation Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
UA86042C2 (en) 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
US7375090B2 (en) 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
WO2005063788A1 (ja) * 2003-12-26 2005-07-14 Kissei Pharmaceutical Co., Ltd. ベンズイミダゾール誘導体及びその医薬用途
CN103030617A (zh) 2004-03-16 2013-04-10 贝林格尔.英格海姆国际有限公司 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
EP1731524A4 (en) * 2004-03-31 2009-05-20 Kissei Pharmaceutical PHENOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE DERIVATIVE, AND ITS MEDICINAL USE
JP2005350375A (ja) 2004-06-09 2005-12-22 Kikkoman Corp 血中尿酸値低下剤
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
DE102004034690A1 (de) 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
WO2006010557A1 (de) 2004-07-27 2006-02-02 Boehringer Ingelheim International Gmbh D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2006018150A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
JP2006117651A (ja) 2004-09-27 2006-05-11 Taisho Pharmaceut Co Ltd Ｓｇｌｔ２の活性阻害剤
WO2006035796A1 (ja) 2004-09-29 2006-04-06 Kissei Pharmaceutical Co., Ltd. １－（β－Ｄ－グリコピラノシル）－３－置換含窒素ヘテロ環化合物、それを含有する医薬組成物及びその医薬用途
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CN100457143C (zh) * 2004-11-29 2009-02-04 成都华西天然药物有限公司 一种治疗痛风的药物
DE102004058449A1 (de) 2004-12-03 2006-06-14 Merck Patent Gmbh Tetrahydropyranderivate
TW200637839A (en) * 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
WO2007025943A2 (en) 2005-08-30 2007-03-08 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
AR059489A1 (es) * 2006-02-15 2008-04-09 Boehringer Ingelheim Vetmed Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
EP2076503B1 (en) 2006-05-19 2013-07-17 Taisho Pharmaceutical Co., Ltd C-phenyl glycitol compound for the treatment of diabetes
US7803778B2 (en) * 2006-05-23 2010-09-28 Theracos, Inc. Glucose transport inhibitors and methods of use
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
AU2007316613B2 (en) * 2006-11-09 2013-11-28 Boehringer Ingelheim International Gmbh Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions
TW200904405A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
WO2009143021A1 (en) * 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Method for treating and preventing kidney stones employing an sglt2 inhibitor and composition containing same

Similar Documents

Publication Publication Date Title
JP2011520965A5 (https=)
JP2012184234A5 (https=)
SG10201407013QA (en) Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
ES2509892T3 (es) Administración de un agente para limpieza del intestino y antibiótico para el tratamiento de enfermedad intestinal
JP2014532647A5 (https=)
JP2011515349A5 (https=)
SG10201903512SA (en) Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases
JP2013528655A5 (https=)
JP2014012726A5 (https=)
JP2015057427A5 (https=)
ES2569354T3 (es) Forma farmacéutica multiparticular, que contiene productos activos de ácido nucleico de formulación mucoadhesiva, así como un procedimiento para la obtención de la forma farmacéutica
Epstein Targeting memory Th2 cells for the treatment of allergic asthma
Yin et al. Probucol for the prevention of cystatin C-based contrast-induced acute kidney injury following primary or urgent angioplasty: a randomized, controlled trial
JP2017504649A5 (https=)
RU2010153904A (ru) Ниацин-содержащие композиции с модифицированным высвобождением
RU2015139758A (ru) Хиназолины в качестве ингибиторов киназы
JP2014532760A5 (https=)
JP2013087119A5 (https=)
JP2011527678A5 (https=)
JP2014532758A5 (https=)
TW200735874A (en) Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
CN106164059A (zh) 用天冬酰胺内肽酶（aep）抑制剂以及相关组合物对神经退行性疾病的治疗
JP2013507382A5 (https=)
JP2014532759A5 (https=)
JP2008533079A5 (https=)